Neuroprotection with rasagiline in patients with macula-off retinal detachment: A randomized controlled pilot study

Yu, Siqing; Framme, Carsten; Menke, Marcel Nico; Berger, Lieselotte Erika; Zinkernagel, Martin; Munk, Marion Rohit; Wolf, Sebastian; Ebneter, Andreas (2020). Neuroprotection with rasagiline in patients with macula-off retinal detachment: A randomized controlled pilot study. Scientific Reports, 10(1), p. 4948. Nature Publishing Group 10.1038/s41598-020-61835-0

Preview

Text 41598_2020_Article_61835.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview

We aimed to evaluate the neuroprotective efficacy of rasagiline in pseudophakic patients who had surgery for macula-off rhegmatogenous retinal detachment (RRD). This was a 6-month, prospective, randomized, double-blind, placebo-controlled pilot study. Patients presenting with acute macula-off RRD were recruited and randomized 1:1 to receive rasagiline 1mg/day or placebo for 7 days. Best-corrected visual acuity (BCVA) and optical coherence tomography were acquired 1 day before as well as 2 days, 3 weeks, 3 months and 6 months after surgery. We screened 26 patients with RRD whereof 23 were eventually included and randomized. The primary outcome was final BCVA. Secondary outcomes included central retinal thickness (CRT) and adverse events (AE). We evaluated photoreceptor cells (prc) recovery through morphological measurements. The baseline characteristics were comparable between groups. BCVA significantly improved in both groups (letters gained: rasagiline 61.5±18.1 vs placebo 55.3±29.2, p=0.56), but no significant inter-group difference was found at any visit. CRT was stable 3 weeks after surgery onwards, with no inter-group difference. No treatment-emergent AE occurred. Significant prc restoration was observed from 3 weeks to 6 months after surgery, without inter-group difference at either visit. Ellipsoid zone integrity (β=0.517, p=0.008) and foveal bulge (β=0.387, p=0.038) were significant predictors of good final BCVA. In conclusion, perioperative oral treatment with rasagiline 1mg/day for 7 days did not show significant benefits on visual or anatomical outcomes in macula-off RRD patients.

Interest & Impact

Downloads

118 since deposited on 21 Apr 2020
15 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item